Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Camacho

Cardiovascular Disease National City, CA Medical Doctor

NPI 1699759936 CMS profile 167410

1615 Sweetwater Rd, National City, CA 91950

Open in the dashboard

General payments

$12,837

851 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Camacho of National City, CA is reported in the CMS Open Payments database as having received $12,837 across 851 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $883 65
2024 General $1,602 97
2023 General $2,328 150
2022 General $2,379 173
2021 General $2,079 151
2020 General $1,186 62
2019 General $2,381 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Camacho
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Benjamin Camacho were reported at $883. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Benjamin Camacho Cardiovascular Disease median Middle half National median
2019 $2,381 $450 $127–$1,392 $163
2020 $1,186 $242 $77–$751 $114
2021 $2,079 $335 $101–$1,037 $132
2022 $2,379 $395 $121–$1,211 $149
2023 $2,328 $443 $136–$1,283 $160
2024 $1,602 $450 $136–$1,323 $164
2025 $883 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,540 53 payments
  2. Medtronic, Inc. $1,171 30 payments
  3. Novartis Pharmaceuticals Corporation $1,127 161 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,115 89 payments
  5. Actelion Pharmaceuticals US, Inc. $977 164 payments
  6. AstraZeneca Pharmaceuticals LP $839 34 payments
  7. Janssen Pharmaceuticals, Inc $776 58 payments
  8. Merck Sharp & Dohme Corporation $707 32 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $616 40 payments
  10. Abbott Laboratories $587 24 payments
  11. Other $3,382 166 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,821 848 payments
  2. Education $17 3 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $932 158 payments
  2. Micra $863 13 payments
  3. OPSUMIT $852 148 payments
  4. ENTRESTO $775 108 payments
  5. VERQUVO $706 32 payments
  6. JARDIANCE $693 54 payments
  7. XARELTO $653 57 payments
  8. Kerendia $616 40 payments
  9. WATCHMAN $524 24 payments
  10. WATCHMAN Access System $462 10 payments
  11. Other $6,749 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,500

Median for Internal Medicine: 777

Drug cost

$1,597,335

Median for Internal Medicine: $73,373

Branded share of claims

51.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 645 $757,349
Xarelto Rivaroxaban Brand 374 $371,326
Jardiance Empagliflozin Brand 182 $193,801
Eliquis Apixaban Brand 107 $122,763
Ranolazine Er Ranolazine Brand 382 $35,002
Januvia Sitagliptin Phosphate Brand 23 $26,725
Kerendia Finerenone Brand 28 $25,326
Farxiga Dapagliflozin Propanediol Brand 26 $21,660
Brilinta Ticagrelor Brand 20 $15,628
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 465 $5,197

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$429,628

Of which drugs: $2,830

Medicare patients

341

Average age 75

Services billed

5,677

188 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Diabetes 57%
Arthritis 44%
Chronic kidney disease 36%
Atrial fibrillation 25%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 135 540 $2,668
Infusion, normal saline solution, 250 cc J7050 Office 244 314 $162

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $254
$254 182 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $250
$250 28 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $125
$125 645 —
XARELTO
  • Janssen Pharmaceuticals, Inc $98
$98 374 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

851 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record